Solstein Capital’s NovoCure NVCR Stock Holding History

Solstein Capital’s Portfolio NVCR Stock Details NVCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-500	Closed	-$8.9K	–	494
2025 Q2	$8.9K	Hold	500	–	–	﹤0.01%	346
2025 Q1	$8.91K	Hold	500	–	–	0.01%	244
2024 Q4	$14.9K	Hold	500	–	–	0.01%	221
2024 Q3	$7.82K	Hold	500	–	–	﹤0.01%	255
2024 Q2	$8.56K	Hold	500	–	–	0.01%	245
2024 Q1	$7.82K	Hold	500	–	–	0.01%	246
2023 Q4	$7.46K	Hold	500	–	–	0.01%	246
2023 Q3	$8.07K	Hold	500	–	–	0.01%	241
2023 Q2	$20.8K	Hold	500	–	–	0.02%	180
2023 Q1	$30.1K	Hold	500	–	–	0.03%	158
2022 Q4	$36.7K	Hold	500	–	–	0.03%	162
2022 Q3	$38K	Hold	500	–	–	0.03%	171
2022 Q2	$35K	Hold	500	–	–	0.03%	196
2022 Q1	$41K	Hold	500	–	–	0.03%	211
2021 Q4	$38K	Sell	500 -500	-50%	-$50.2K	0.02%	232
2021 Q3	$116K	Hold	1,000	–	–	0.07%	166
2021 Q2	$222K	Buy	+1,000	New	+$195K	0.27%	89

Other funds holding NVCR

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

QCM

Quantinno Capital Management New York $59.9B AUM 28.07% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Solstein Capital's NVCR Position: Q3 2025 in Review

Solstein Capital sold out of NovoCure (NVCR) in Q3 2025, closing a stake of 500 shares — an estimated $8.9K sold.

Solstein Capital first reported a position in NVCR in Q2 2021 and held it in 17 quarters. The position peaked at $222K in Q2 2021. 244 funds tracked by Wall St. Rank hold NVCR as of Q3 2025.

Solstein Capital reported no remaining NovoCure position as of Q3 2025 after selling out during the quarter.
Solstein Capital sold 500 NovoCure shares in Q3 2025, an estimated $8.9K.
Solstein Capital first reported a position in NovoCure in Q2 2021 and held it in 17 quarters.
Solstein Capital's NovoCure position peaked at $222K in Q2 2021.
244 funds tracked by Wall St. Rank held NovoCure as of Q3 2025.

Based on Solstein Capital's 13F filing for Q3 2025, filed 12 Nov 2025.